BABA vs MGIH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed financial profile for Alibaba (BABA), with a weak Piotroski F-Score of 4/9 indicating suboptimal financial health, and no available Altman Z-Score limiting distress risk assessment. While valuation metrics appear favorable relative to peers—especially a Price/Sales of 0.41 and Forward P/E of 19.50—earnings growth is sharply negative (YoY EPS down 71%), and recent quarterly beats have reversed into consistent misses over the last four quarters. Strong insider sentiment and a bullish analyst consensus (strong_buy) contrast with deteriorating profitability and weak technical trends (10/100). The stock trades significantly above the Graham Number ($102.68) and intrinsic value estimate ($51.38), suggesting overvaluation unless growth rebounds materially.
MGIH presents a contradictory profile with a stable Piotroski F-Score of 5/9 but severe operational decay. While the balance sheet remains healthy with low debt and strong liquidity ratios, the company is suffering from a significant 24% year-over-year revenue decline and deep negative profit margins (-24.93%). The lack of an Altman Z-Score and Graham Number reflects a lack of profitability and valuation stability, while a 0/100 technical trend indicates strong bearish momentum.
Compare Another Pair
Related Comparisons
BABA vs MGIH: Head-to-Head Comparison
This page compares Alibaba Group Holding Limited (BABA) and Millennium Group International Holdings Limited (MGIH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.